FAQ: Research Activities and Laboratories
Some OVPR staff are working remotely until further notice. Although there may be some delays to processing time or communications, OVPR will continue to provide full services to the best of our abilities. Staff are reachable during normal business hours (8:30am-5pm) via email and can set-up meetings via phone or other virtual platforms. Contact information can be found here . Any concerns should be directed to the Directors of respective units. Please find that information here . Announcements will be sent via our listservs and posted here as well as on our website if there are changes.
Many federal funding agencies are posting FAQs and guidance related to proposal submission and award management:
In addition, the Council on Governmental Relations has compiled Frequently Asked Questions Regarding COVID-19’s Impact on Federal Awards on topics related to Travel Charges, including Cancellation Costs, Remote Work Environments, Project Progress Obligations, Salary Charges etc.
The Human Research Protection Program will continue to receive and review new studies. For studies that are approvable, but involve in-person interactions with study subjects and do not have the potential for direct benefit, the IRB will approve the study but with a stipulation that the study cannot begin enrollment until official guidance (e.g., government) states that social distancing is no longer necessary.
For studies in which there is no direct benefit to subjects or where there is subjects travel for research purposes (and no direct benefit), studies must be paused, effective immediately or as soon as can be implemented. Procedures such as telephone contact or monitoring or remote data collection, if part of such studies, may continue.
Studies in which there is direct benefit to subjects may continue. If possible, these studies should be performed remotely. This would include the collection of safety data (based on the ability to detect potential adverse events). It is suggested that laboratory tests or imaging needed for safety monitoring occur at local laboratories or clinics.
Although there may be delays in processing time or communications, OTLIR will continue to provide full services to the best of our abilities. Invention disclosures may continue to be submitted through the inventor portal accessed here. They will continue to be docketed and reviewed by our office. Confidentiality agreements for clinical trials and for other purposes will continue to be negotiated and signed. Material transfer agreements for tangible materials to be sent to and from campus will also continue to be negotiated and signed. It is unclear if there will be disruptions with courier services and/or shipping and receiving.